Published in Onco Targets Ther on September 14, 2016
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors | NCT01106508
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | NCT01842646
Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment. Stem Cells Int (2017) 0.75
Basal Cell Carcinoma Surgery: Simple Undermining Approach in Two Patients with Different Tumour Locations. Open Access Maced J Med Sci (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature (2000) 10.04
Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol (2010) 8.55
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science (1996) 8.06
Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell (1996) 7.86
Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature (1998) 7.43
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07
Teratogen-mediated inhibition of target tissue response to Shh signaling. Science (1998) 5.28
The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet (1996) 4.36
Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer (2008) 4.34
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A (2007) 4.15
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development (1998) 3.89
The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol (2013) 3.84
Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol (1994) 3.49
Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol (2003) 3.22
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A (2009) 3.13
Gli proteins in development and disease. Annu Rev Cell Dev Biol (2011) 3.04
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med (2010) 2.86
Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc Natl Acad Sci U S A (2009) 2.41
A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol (2009) 2.21
Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol (1998) 2.00
Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol (2010) 1.93
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol (2015) 1.90
Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol (2005) 1.90
Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol (1989) 1.89
Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol (2014) 1.86
Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene (2009) 1.85
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett (2010) 1.68
Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev (2004) 1.58
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res (2014) 1.35
Teratogenic compounds of Veratrum californicum (Durand). V. Comparison of cyclopian effects of steroidal alkaloids from the plant and structurally related compounds from other sources. Teratology (1968) 1.27
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res (2013) 1.25
Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res (2011) 1.25
Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet (1999) 1.15
A dose-response curve for sun exposure and basal cell carcinoma. Int J Cancer (1995) 1.11
Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists. J Med Chem (2008) 1.07
Cyclopamine and related steroidal alkaloid teratogens: their occurrence, structural relationship, and biologic effects. Lipids (1978) 1.06
Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg Med Chem (2008) 1.06
Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res (2011) 1.02
Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. Acta Oncol (1996) 0.90
Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol (1990) 0.87
Chronologic evaluation of teratogenicity in sheep fed Veratrum californicum. J Am Vet Med Assoc (1965) 0.87
The role of radiation therapy in the management of skin cancers. Dermatol Clin (2011) 0.87
An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clin Cancer Res (2015) 0.85
Introduction of wild-type patched gene suppresses the oncogenic potential of human squamous cell carcinoma cell lines including A431. Oncogene (2002) 0.84
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol (2016) 0.84
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatol (2016) 0.83
Teratogenic compounds of Veratrum californicum (Durand). VII. The structure of the glycosidic alkaloid cycloposine. Steroids (1969) 0.79
Basal cell naevus syndrome: an update on genetics and treatment. Br J Dermatol (2015) 0.78